346,000 Shares in Humana Inc. (NYSE:HUM) Bought by Baupost Group LLC MA

Baupost Group LLC MA acquired a new stake in Humana Inc. (NYSE:HUM - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 346,000 shares of the insurance provider's stock, valued at approximately $87,784,000. Humana accounts for 2.5% of Baupost Group LLC MA's investment portfolio, making the stock its 15th biggest holding. Baupost Group LLC MA owned about 0.29% of Humana as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter worth about $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana during the fourth quarter valued at approximately $30,000. LFA Lugano Financial Advisors SA raised its position in shares of Humana by 56.3% during the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management acquired a new stake in Humana in the 4th quarter valued at $33,000. Finally, Atwood & Palmer Inc. increased its stake in Humana by 64.5% during the 4th quarter. Atwood & Palmer Inc. now owns 153 shares of the insurance provider's stock valued at $39,000 after purchasing an additional 60 shares in the last quarter. Institutional investors own 92.38% of the company's stock.

Analyst Ratings Changes

HUM has been the subject of a number of recent research reports. JPMorgan Chase & Co. decreased their price objective on Humana from $257.00 to $256.00 and set a "neutral" rating for the company in a report on Tuesday, February 18th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Truist Financial upped their target price on Humana from $290.00 to $325.00 and gave the company a "hold" rating in a report on Friday, April 11th. Mizuho boosted their price target on shares of Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $283.00 price objective on shares of Humana in a research note on Wednesday, February 12th. Seventeen analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $284.90.

Humana Trading Down 7.4 %

HUM stock traded down $21.20 on Friday, reaching $264.41. The company's stock had a trading volume of 3,670,273 shares, compared to its average volume of 1,757,258. The business has a fifty day simple moving average of $265.90 and a two-hundred day simple moving average of $269.86. The firm has a market cap of $31.91 billion, a PE ratio of 26.57, a PEG ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts forecast that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.34%. Humana's payout ratio is currently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.